Appendix 4G

Key to Disclosures Corporate Governance Council Principles and Recommendations

Name of entity		
Medibio Lim	nited	
ABN/ARBN 58 008 130 3	336	Financial year ended 30 June 2017
Our corporate g	governance statement ²	for the above period above can be found at: ³
☐ these pages	s of our annual report:	
	URL on our website:	http://www.medibio.com.au/corporate-governance/
The Corporate the board.	Governance Statement	t is accurate and up to date as at 30 June 2017 and has been approved by
The annexure in	ncludes a key to where	e our corporate governance disclosures can be located.
Date here:	31 October 2017	1
Sign here:	Company Secretar	←
Print name:	Robert Lees	

Under Listing Rule 4.7.4, if an entity chooses to include its corporate governance statement on its website rather than in its annual report, it must lodge a copy of the corporate governance statement with ASX at the same time as it lodges its annual report with ASX. The corporate governance statement must be current as at the effective date specified in that statement for the purposes of rule 4.10.3.

1

¹ Under Listing Rule 4.7.3, an entity must lodge with ASX a completed Appendix 4G at the same time as it lodges its annual report with ASX.

Listing Rule 4.10.3 requires an entity that is included in the official list as an ASX Listing to include in its annual report either a corporate governance statement that meets the requirements of that rule or the URL of the page on its website where such a statement is located. The corporate governance statement must disclose the extent to which the entity has followed the recommendations set by the ASX Corporate Governance Council during the reporting period. If the entity has not followed a recommendation for any part of the reporting period, its corporate governance statement must separately identify that recommendation and the period during which it was not followed and state its reasons for not following the recommendation and what (if any) alternative governance practices it adopted in lieu of the recommendation during that period.

² "Corporate governance statement" is defined in Listing Rule 19.12 to mean the statement referred to in Listing Rule 4.10.3 which discloses the extent to which an entity has followed the recommendations set by the ASX Corporate Governance Council during a particular reporting period.

³ Mark whichever option is correct and then complete the page number(s) of the annual report, or the URL of the web page, where the entity's corporate governance statement can be found.

ANNEXURE – KEY TO CORPORATE GOVERNANCE DISCLOSURES

Corporate Governance Council recommendation		We have followed the recommendation in full for the whole of the period above. We have disclosed	We have <u>NOT</u> followed the recommendation in full for the whole of the period above. We have disclosed
PRIN	PRINCIPLE 1 – LAY SOLID FOUNDATIONS FOR MANAGEMENT AND OVERSIGHT		
1.1	A listed entity should disclose: (a) the respective roles and responsibilities of its board and management; and (b) those matters expressly reserved to the board and those delegated to management.	the fact that we follow this recommendation: in our Corporate Governance Statement OR at this location: Insert location here and information about the respective roles and responsibilities of our board and management (including those matters expressly reserved to the board and those delegated to management): at this location: http://www.medibio.com.au/corporate-governance/ Insert location here	an explanation why that is so in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable
1.2	A listed entity should: (a) undertake appropriate checks before appointing a person, or putting forward to security holders a candidate for election, as a director; and (b) provide security holders with all material information in its possession relevant to a decision on whether or not to elect or re-elect a director.	the fact that we follow this recommendation: in our Corporate Governance Statement OR at this location: _ http://www.medibio.com.au/corporate-governance/ Insert location here	an explanation why that is so in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable
1.3	A listed entity should have a written agreement with each director and senior executive setting out the terms of their appointment.	the fact that we follow this recommendation: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable
1.4	The company secretary of a listed entity should be accountable directly to the board, through the chair, on all matters to do with the proper functioning of the board.	the fact that we follow this recommendation: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable

Corporate Governance Council recommendation		We have followed the recommendation in full for the whole of the period above. We have disclosed	We have <u>NOT</u> followed the recommendation in full for the whole of the period above. We have disclosed
1.5	A listed entity should: (a) have a diversity policy which includes requirements for the board or a relevant committee of the board to set measurable objectives for achieving gender diversity and to assess annually both the objectives and the entity's progress in achieving them; (b) disclose that policy or a summary of it; and (c) disclose as at the end of each reporting period the measurable objectives for achieving gender diversity set by the board or a relevant committee of the board in accordance with the entity's diversity policy and its progress towards achieving them and either: (1) the respective proportions of men and women on the board, in senior executive positions and across the whole organisation (including how the entity has defined "senior executive" for these purposes); or (2) if the entity is a "relevant employer" under the Workplace Gender Equality Act, the entity's most recent "Gender Equality Indicators", as defined in and published under that Act.	the fact that we have a diversity policy that complies with paragraph (a): in our Corporate Governance Statement OR at this location: and a copy of our diversity policy or a summary of it: at this location: http://www.medibio.com.au/corporate-governance the measurable objectives for achieving gender diversity set by the board or a relevant committee of the board in accordance with our diversity policy and our progress towards achieving them: in our Corporate Governance Statement OR at this location: Insert location here at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable

Corporate Governance Council recommendation		We have followed the recommendation in full for the whole of the period above. We have disclosed	We have <u>NOT</u> followed the recommendation in full for the whole of the period above. We have disclosed
1.6	A listed entity should: (a) have and disclose a process for periodically evaluating the performance of the board, its committees and individual directors; and (b) disclose, in relation to each reporting period, whether a performance evaluation was undertaken in the reporting period in accordance with that process.	the evaluation process referred to in paragraph (a): in our Corporate Governance Statement OR at this location: Insert location here and the information referred to in paragraph (b): in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable
1.7	A listed entity should: (a) have and disclose a process for periodically evaluating the performance of its senior executives; and (b) disclose, in relation to each reporting period, whether a performance evaluation was undertaken in the reporting period in accordance with that process.	the evaluation process referred to in paragraph (a): in our Corporate Governance Statement OR at this location: Insert location here and the information referred to in paragraph (b): in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable

Corporate Governance Council recommendation		We have followed the recommendation in full for the whole of the period above. We have disclosed	We have NOT followed the recommendation in full for the whole of the period above. We have disclosed
PRIN	CIPLE 2 - STRUCTURE THE BOARD TO ADD VALUE	<u> </u>	
2.1	The board of a listed entity should: (a) have a nomination committee which: (1) has at least three members, a majority of whom are independent directors; and (2) is chaired by an independent director, and disclose: (3) the charter of the committee; (4) the members of the committee; and (5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; OR (b) if it does not have a nomination committee, disclose that fact and the processes it employs to address board succession issues and to ensure that the board has the appropriate balance of skills, knowledge, experience, independence and diversity to enable it to discharge its duties and responsibilities effectively.	[If the entity complies with paragraph (a):] the fact that we have a nomination committee that complies with paragraphs (1) and (2): □ at this location: and a copy of the charter of the committee: □ at this location: http://www.medibio.com.au/corporate-governance/ and the information referred to in paragraphs (4) and (5): □ in our Corporate Governance Statement OR □ at this location: Insert location here [If the entity complies with paragraph (b):] the fact that we do not have a nomination committee and the processes we employ to address board succession issues and to ensure that the board has the appropriate balance of skills, knowledge, experience, independence and diversity to enable it to discharge its duties and responsibilities effectively: □ at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable
2.2	A listed entity should have and disclose a board skills matrix setting out the mix of skills and diversity that the board currently has or is looking to achieve in its membership.	our board skills matrix: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable

Corporate Governance Council recommendation		We have followed the recommendation in full for the whole of the period above. We have disclosed	We have <u>NOT</u> followed the recommendation in full for the whole of the period above. We have disclosed
2.3	A listed entity should disclose: (a) the names of the directors considered by the board to be independent directors; (b) if a director has an interest, position, association or relationship of the type described in Box 2.3 but the board is of the opinion that it does not compromise the independence of the director, the nature of the interest, position, association or relationship in question and an explanation of why the board is of that opinion; and (c) the length of service of each director.	the names of the directors considered by the board to be independent directors: ✓ in our Corporate Governance Statement OR □ at this location: Insert location here where applicable, the information referred to in paragraph (b): ✓ in our Corporate Governance Statement OR □ at this location: Insert location here the length of service of each director: ✓ in our Corporate Governance Statement OR □ at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement
2.4	A majority of the board of a listed entity should be independent directors.	the fact that we follow this recommendation: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable
2.5	The chair of the board of a listed entity should be an independent director and, in particular, should not be the same person as the CEO of the entity.	the fact that we follow this recommendation: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable

Corporate Governance Council recommendation		We have followed the recommendation in full for the whole of the period above. We have disclosed	We have <u>NOT</u> followed the recommendation in full for the whole of the period above. We have disclosed
2.6	A listed entity should have a program for inducting new directors and provide appropriate professional development opportunities for directors to develop and maintain the skills and knowledge needed to perform their role as directors effectively.	the fact that we follow this recommendation: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable
PRIN	CIPLE 3 – ACT ETHICALLY AND RESPONSIBLY		
3.1	A listed entity should: (a) have a code of conduct for its directors, senior executives and employees; and (b) disclose that code or a summary of it.	our code of conduct or a summary of it: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement
PRIN	 CIPLE 4 – SAFEGUARD INTEGRITY IN CORPORATE		
4.1	The board of a listed entity should: (a) have an audit committee which: (1) has at least three members, all of whom are non-executive directors and a majority of whom are independent directors; and (2) is chaired by an independent director, who is not the chair of the board, and disclose: (3) the charter of the committee; (4) the relevant qualifications and experience of the members of the committee; and (5) in relation to each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; OR (b) if it does not have an audit committee, disclose that fact and the processes it employs that independently verify and safeguard the integrity of its corporate reporting, including the processes for the appointment and removal of the external auditor and the rotation of the audit engagement partner.	[If the entity complies with paragraph (a):] the fact that we have an audit committee that complies with paragraphs (1) and (2): ✓ in our Corporate Governance Statement OR at this location: Insert location here and a copy of the charter of the committee: ✓ at this location: http://www.medibio.com.au/corporate-governance/ Insert location here and the information referred to in paragraphs (4) and (5): ✓ in our Corporate Governance Statement OR at this location: Insert location here [If the entity complies with paragraph (b):]	an explanation why that is so in our Corporate Governance Statement

Corpo	rate Governance Council recommendation	We have followed the recommendation in full for the whole of the period above. We have disclosed	We have <u>NOT</u> followed the recommendation in full for the whole of the period above. We have disclosed
		the fact that we do not have an audit committee and the processes we employ that independently verify and safeguard the integrity of our corporate reporting, including the processes for the appointment and removal of the external auditor and the rotation of the audit engagement partner: in our Corporate Governance Statement OR at this location: Insert location here	
4.2	The board of a listed entity should, before it approves the entity's financial statements for a financial period, receive from its CEO and CFO a declaration that, in their opinion, the financial records of the entity have been properly maintained and that the financial statements comply with the appropriate accounting standards and give a true and fair view of the financial position and performance of the entity and that the opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.	the fact that we follow this recommendation: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement
4.3	A listed entity that has an AGM should ensure that its external auditor attends its AGM and is available to answer questions from security holders relevant to the audit.	the fact that we follow this recommendation: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement OR we are an externally managed entity that does not hold an annual general meeting and this recommendation is therefore not applicable
PRIN	CIPLE 5 – MAKE TIMELY AND BALANCED DISCLOS	SURE	
5.1	A listed entity should: (a) have a written policy for complying with its continuous disclosure obligations under the Listing Rules; and (b) disclose that policy or a summary of it.	our continuous disclosure compliance policy or a summary of it: ✓ in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement

		We have followed the recommendation in full for the whole of the period above. We have disclosed	We have <u>NOT</u> followed the recommendation in full for the whole of the period above. We have disclosed
PRIN	CIPLE 6 – RESPECT THE RIGHTS OF SECURITY HO	<u>LDERS</u>	
6.1	A listed entity should provide information about itself and its governance to investors via its website.	information about us and our governance on our website: at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement
6.2	A listed entity should design and implement an investor relations program to facilitate effective two-way communication with investors.	the fact that we follow this recommendation: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement
6.3	A listed entity should disclose the policies and processes it has in place to facilitate and encourage participation at meetings of security holders.	our policies and processes for facilitating and encouraging participation at meetings of security holders: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement OR we are an externally managed entity that does not hold periodic meetings of security holders and this recommendation is therefore not applicable
6.4	A listed entity should give security holders the option to receive communications from, and send communications to, the entity and its security registry electronically.	the fact that we follow this recommendation: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement
PRIN	CIPLE 7 – RECOGNISE AND MANAGE RISK		
7.1	The board of a listed entity should: (a) have a committee or committees to oversee risk, each of which: (1) has at least three members, a majority of whom are independent directors; and (2) is chaired by an independent director, and disclose: (3) the charter of the committee; (4) the members of the committee; and	[If the entity complies with paragraph (a):] the fact that we have a committee or committees to oversee risk that comply with paragraphs (1) and (2): in our Corporate Governance Statement OR at this location: Insert location here and a copy of the charter of the committee:	an explanation why that is so in our Corporate Governance Statement

Corpo	orate Governance Council recommendation	We have followed the recommendation in full for the whole of the period above. We have disclosed	We have <u>NOT</u> followed the recommendation in full for the whole of the period above. We have disclosed
	 (5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; OR (b) if it does not have a risk committee or committees that satisfy (a) above, disclose that fact and the processes it employs for overseeing the entity's risk management framework. 	at this location: Insert location here	
7.2	The board or a committee of the board should: (a) review the entity's risk management framework at least annually to satisfy itself that it continues to be sound; and (b) disclose, in relation to each reporting period, whether such a review has taken place.	the fact that we follow this recommendation: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement
7.3	A listed entity should disclose: (a) if it has an internal audit function, how the function is structured and what role it performs; OR (b) if it does not have an internal audit function, that fact and the processes it employs for evaluating and continually improving the effectiveness of its risk management and internal control processes.	[If the entity complies with paragraph (a):] how our internal audit function is structured and what role it performs: in our Corporate Governance Statement OR at this location: Insert location here [If the entity complies with paragraph (b):] the fact that we do not have an internal audit function and the processes we employ for evaluating and continually	an explanation why that is so in our Corporate Governance Statement

Corporate Governance Council recommendation		We have followed the recommendation in full for the whole of the period above. We have disclosed	We have <u>NOT</u> followed the recommendation in full for the whole of the period above. We have disclosed
		improving the effectiveness of our risk management and internal control processes: ✓ in our Corporate Governance Statement OR at this location: Insert location here	
7.4	A listed entity should disclose whether it has any material exposure to economic, environmental and social sustainability risks and, if it does, how it manages or intends to manage those risks.	whether we have any material exposure to economic, environmental and social sustainability risks and, if we do, how we manage or intend to manage those risks: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement
PRIN	CIPLE 8 – REMUNERATE FAIRLY AND RESPONSIBI	<u>LY</u>	
8.1	The board of a listed entity should: (a) have a remuneration committee which: (1) has at least three members, a majority of whom are independent directors; and (2) is chaired by an independent director, and disclose: (3) the charter of the committee; (4) the members of the committee; and (5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; OR (b) if it does not have a remuneration committee, disclose that fact and the processes it employs for setting the level and composition of remuneration for directors and senior executives and ensuring that such remuneration is appropriate and not excessive.	[If the entity complies with paragraph (a):] the fact that we have a remuneration committee that complies with paragraphs (1) and (2): performs: □ in our Corporate Governance Statement OR □ at this location: Insert location here and a copy of the charter of the committee: □ at this location: http://www.medibio.com.au/corporate-governance/ Insert location here and the information referred to in paragraphs (4) and (5): □ in our Corporate Governance Statement OR □ at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable

Corporate Governance Council recommendation		We have followed the recommendation in full for the whole of the period above. We have disclosed	We have <u>NOT</u> followed the recommendation in full for the whole of the period above. We have disclosed
		[If the entity complies with paragraph (b):] the fact that we do not have a remuneration committee and the processes we employ for setting the level and composition of remuneration for directors and senior executives and ensuring that such remuneration is appropriate and not excessive: in our Corporate Governance Statement OR at this location: Insert location here	
8.2	A listed entity should separately disclose its policies and practices regarding the remuneration of non-executive directors and the remuneration of executive directors and other senior executives.	separately our remuneration policies and practices regarding the remuneration of non-executive directors and the remuneration of executive directors and other senior executives: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable
8.3	A listed entity which has an equity-based remuneration scheme should: (a) have a policy on whether participants are permitted to enter into transactions (whether through the use of derivatives or otherwise) which limit the economic risk of participating in the scheme; and (b) disclose that policy or a summary of it.	our policy on this issue or a summary of it: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement OR we do not have an equity-based remuneration scheme and this recommendation is therefore not applicable OR we are an externally managed entity and this recommendation is therefore not applicable

Corporate Governance Council recommendation		We have followed the recommendation in full for the whole of the period above. We have disclosed	We have \underline{NOT} followed the recommendation in full for the whole of the period above. We have disclosed
<u>ADDI</u>	TIONAL DISCLOSURES APPLICABLE TO EXTERNA	LLY MANAGED LISTED ENTITIES	
-	Alternative to Recommendation 1.1 for externally managed listed entities: The responsible entity of an externally managed listed entity should disclose: (a) the arrangements between the responsible entity and the listed entity for managing the affairs of the listed entity; (b) the role and responsibility of the board of the responsible entity for overseeing those arrangements.	the information referred to in paragraphs (a) and (b): in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement
-	Alternative to Recommendations 8.1, 8.2 and 8.3 for externally managed listed entities: An externally managed listed entity should clearly disclose the terms governing the remuneration of the manager.	the terms governing our remuneration as manager of the entity: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement

Corporate Governance Statement

This document discloses the extent to which Medibio Limited ABN 58 008 130 336 ('Medibio' or 'Company') has followed the recommendations set by the ASX Corporate Governance Council in the third edition of its Corporate Governance Principles and Recommendations (ASX Recommendations) during the relevant part of the reporting period.

This document is current as at 30 June 2017 and has been approved by the board of the Company.

PRINCIPLES AND RECOMMENDATIONS	COMPLY (YES/NO)	EXPLANATION
Principle 1: Lay solid foundations for management and oversight		
Recommendation 1.1		
A listed entity should disclose:		Refer Section 3 of the Company's Board Charter for further detail
(a) the respective roles and responsibilities of its board and	Yes	which is located on the Company's website at the following link:
management; and		http://www.medibio.com.au/corporate-governance/
(b) b) those matters expressly reserved to the board and those delegated to management.	Yes	
(c)		
Recommendation 1.2		
A listed entity should:		
 a) undertake appropriate checks before appointing a person, or putting forward to security holders a candidate for election, as a director; and 	Yes	Refer to the Company's Board Charter for further detail which is located on the Company's website at the following link: http://www.medibio.com.au/corporate-governance/
 b) provide security holders with all material information relevant to a decision on whether or not to elect or re-elect a director. 	Yes	Information is included in The Company's Notice of Meetings to shareholders.
Recommendation 1.3		
A listed entity should have a written agreement with each director and senior executive setting out the terms of their appointment.	Yes	Refer to the Company's Board Charter for further detail which is located on the Company's website at the following link: http://www.medibio.com.au/corporate-governance/
		Details of executive contracts in place are detailed in the Company's Annual Remuneration Report in the 2017 Annual Report

		(YES/NO)				
			Γ			
Recommendation					5 10 . (6 .1
•	etary of a listed entity should be accountable directly to		Refer Section 8 of			
	n the chair, on all matters to do with the proper	Yes	which is located o			-
functioning of the			http://www.medi	bio.com.au/corp	oorate-governance	<u>e/</u>
Recommendation						
A listed entity show				5.1		6 6 11 1 11
	ersity policy which includes requirements for the board:	Yes	Refer to Section 2	•		
	measurable objectives for achieving gender diversity;		which is located o			-
	o assess annually both the objectives and the entity's		http://www.medi	bio.com.au/corp	oorate-governance	e/
progress	in achieving them;		5		6.1	
(1.) 1: 1 .1			Due to the current	•	_	
(b) disclose tr	nat policy or a summary or it; and		Board does not co		•	
(- V - 12 1	and the conduction decreased the conduction of	N	objectives in relat	-		
• •	at the end of each reporting period:	No	ensuring that the appropriate mix of skills, experience, expertise and			
	leasurable objectives for achieving gender diversity set		diversity are considered when employing staff at all levels of the			
by the board in accordance with the entity's diversity policy and its progress towards achieving them; and			organisation and when making new senior executive and Board appointments and is satisfied that the composition of employees,			
			• •		•	• •
(ii) eithe			senior executives	and members o	i the Board is app	ropriate.
` '		Yes	The propertion of	waman an tha	hoard waman in	conior avacutiva
(A)	the respective proportions of men and women on the board, in senior executive positions and across the	res	The proportion of positions and won			
	whole organisation (including how the entity has		reporting date wa		iii tile whole orga	iisatioii as at
	defined "senior executive" for these purposes); or		reporting date wa	s as ioliows.	Senior	Whole
	defined senior executive for these purposes), or					
(B)	the entity's "Gender Equality Indicators", as defined in	Not	Condor	Doord	executive	organisation
(D)	the Workplace Gender Equality Act 2012.	Applicable	Gender	Board	positions	
	the Workplace Gender Equality Act 2012.	Арріісавіє	No of women	0	2	5
I			% women	0%	33%	31%
Recommendation	1.6		L		· L	
A listed entity show			Refer to the Comr	any's Board Per	formance Review	Policy for further
(a) have and disclose a process for periodically evaluating the		Yes	Refer to the Company's Board Performance Review Policy for furt detail which is located on the Company's website at the following		•	
performance of the board, its committees and individual directors;			link: http://www.r			_
and						
			The Company did	undertake a per	formance evaluat	ion in the 2017
		Yes	financial year.			

COMPLY EXPLANATION

PRINCIPLES AND RECOMMENDATIONS

PRINCIPLES AND RECOMMENDATIONS	COMPLY (YES/NO)	EXPLANATION
(b) disclose in relation to each reporting period, whether a performance evaluation was undertaken in the reporting period in accordance with that process.		
Recommendation 1.7 A listed entity should: (a) have and disclose a process for periodically evaluating the performance of its senior executives; and (b) disclose in relation to each reporting period, whether a performance evaluation was undertaken in the reporting period in accordance with that process.	Yes Yes	Refer to the Company's Board Performance Review Policy and the Company's Board Charter for further detail which is located on the Company's website at the following link: http://www.medibio.com.au/corporate-governance/ Performance evaluations were undertaken in the 2017 financial year

Principle 2: Structure the board to add value

Recommendation 2.1		
The board of a listed entity should:		The Board has a Nomination & Remuneration Committee to assist the
(a) have a nomination committee which:	(a) Yes	Board in ensuring it is equipped to discharge its responsibilities. The
(i) has at least three members, a majority of whom are independent directors; and	(i) Yes	Committee has guidelines for the nomination and selection of directors and for the operation of the Board. Prior to 30 June 2017 due the size
(ii) is chaired by an independent director,	(ii) Yes	and nature of the Company's operations the Board chose to discuss
and disclose:		those matters usually considered by the Nomination & Remuneration
(iii) the charter of the committee;	(iii)Yes	Committee on a regular basis at the full Board during its regular
(iv) the members of the committee; and (v) as at the end of each	(iv)Yes	meetings.
reporting period, the number of times the committee met throughout	(v) Yes	The Committee Comprises of:
the period and the individual attendances of the members at those		Chris Indermaur – Independent Member & Chairman
meetings; or		Adam Darkins – Independent Member
(b) if it does not have a nomination committee, disclose that fact and the	(b)N/A	Andrew Maxwell – independent Member
processes it employs to address board succession issues and to ensure that the board has the appropriate balance of skills, experience,		Michael Phelps (Peter Carlisle) – independent Member
independence and knowledge of the entity to enable it to discharge its		Refer to the Company's Nomination and Remuneration Committee
duties and responsibilities effectively.		Charter which is located on the Company's website at the following
		link: http://www.medibio.com.au/corporate-governance/

PRINCIPLES AND RECOIVINENDATIONS	(YES/NO)	LAFLANATION
		Refer to the Company's 2017 Annual Report which is located on the Company's website at the following link: http://www.medibio.com.au/corporate-governance/
Recommendation 2.2 A listed entity should have and disclose a board skill matrix setting out the	he Yes	Refer the Company's Board Charter for further detail which is located
mix of skills and diversity that the board currently has or is looking to ach in its membership.		on the Company's website at the following link: http://www.medibio.com.au/corporate-governance/
Recommendation 2.3 A listed entity should disclose:		The Board consists of Seven Directors, six of which (being Chris Indermaur, Adam Darkins, Frank Prendergast, Andrew Maxwell,
(a) the names of the directors considered by the board to be independent directors;	dent Yes	Michael Phelps (alternate – Peter Carlisle) and Patrick Kennedy) are considered independent. The Board considers independence having
(b) if a director has an interest, position, association or relationship of type described in Box 2.3 of the ASX Corporate Governance Principand Recommendation (3rd Edition), but the board is of the opinion it does not compromise the independence of the director, the nat of the interest, position, association or relationship in question an explanation of why the board is of that opinion; and	ples n that cure nd an	regard to the indicia in Box 2.3 in the ASX Recommendations. The Board has considered the holdings of shares in the Company by each independent director and is of the opinion that their respective interests in shares would not materially interfere with, or could be reasonably perceived to interfere with, the independent exercise of their judgement in their position as a Director.
(c) the length of service of each director.	Yes	The Board also considers that Chris Indermaur, Adam Darkins, Frank Prendergast, Andrew Maxwell, Michael Phelps (Alternate – Peter Carlisle) and Patrick Kennedy are otherwise free from any business or other relationship that could materially interfere with, or reasonably be perceived to interfere with, the independent exercise of their judgement, and that each of these Directors is able to fulfil the role of independent Director for the purposes of the ASX Recommendations.
		The other Director – Jack Cosentino is considered by the Board to not be independent on the basis that he is engaged in an executive management role.
		The lengths of service are as follows: • Chris Indermaur – Independent Chairman (2 years, 6 months)

COMPLY EXPLANATION

PRINCIPLES AND RECOMMENDATIONS

PRINCIPLES AND RECOMMENDATIONS	COMPLY (YES/NO)	EXPLANATION
		 Adam Darkins – Independent Member (4 months) Jack Cosentino – Managing Director & CEO (8 months) Frank Prendergast – independent Member (1 years 10 months) Andrew Maxwell – independent Director (8 months) Michael Phelps - Independent Member (4 months) and Patrick Kennedy – Independent Member (4 months)
Recommendation 2.4 A majority of the board of a listed entity should be independent directors.	Yes	As noted above in Recommendation 2.3, the Board is composed of six independent directors and one non-independent directors.
Recommendation 2.5 The chair of the board of a listed entity should be an independent director and, in particular, should not be the same person as the CEO of the entity.	Yes	The Chairman, Chris Indermaur is an independent director. The roles of Chairman and Chief Executive Officer are exercised by different individuals, being Chris Indermaur and Jack Cosentino respectively.
Recommendation 2.6 A listed entity should have a program for inducting new directors and providing appropriate professional development opportunities for continuing directors to develop and maintain the skills and knowledge needed to perform their role as a director effectively.	Yes	The Nomination & Remuneration Committee oversees, reviews and makes recommendations to the Board in relation to the induction, training and development of Non-Executive Directors, to ensure they have access to appropriate learning and development opportunities to develop and maintain the skills and knowledge required to effectively perform in their role as a Director. The Board receives regular updates at board meetings which assist directors in keeping up to date with relevant market and industry developments. There are also procedures in place, agreed by the Board, to enable Directors, in furtherance of their duties, to seek independent professional advice at the Company's expense.

Principle 3: Act ethically and responsibly

Recommendation 3.1	Yes to	For further detail refer to the Company's Code of Conduct for directors
A listed entity should:	all	and senior executives which is located on the Company's website at
(a) have a code of conduct for its directors, senior executives and employees;		the following link:
and		http://www.medibio.com.au/corporate-governance/
(b) disclose that code or a summary of it		

Principle 4: Safeguard integrity in financial reporting

Recommendation 4.1		
The board of a listed entity should:		It is the Board's responsibility to ensure that an effective internal
(a) have an audit committee which:	Yes	control framework exists within the entity. This includes internal
(i) has at least three members, all of whom are non-executive directors and a majority of whom are independent directors; and	Yes	controls to deal with both the effectiveness and efficiency of significant business processes, the safeguarding of assets, the maintenance of
(ii) is chaired by an independent director, who is not the chair of the board, and disclose:	Yes	proper accounting records, and the reliability of financial information as well as non-financial considerations such as the benchmarking of
(iii) the charter of the committee;	Yes	operational key performance indicators. The Board has established an
(iv) the relevant qualifications and experience of the members of the committee; and	Yes	Audit & Risk Committee, which operates under a formal charter approved by the Board, to which it has delegated the responsibility to
 (v) in relation to each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or 	Yes	establish and maintain the framework of internal control and ethical standards for the management of the company. The Committee also provides the Board with additional assurance regarding the reliability of financial information for inclusion in the financial reports. At the
(b) if it does not have an audit committee, disclose that fact and the processes it employs that independently verify and safeguard the integrity of its financial reporting, including the processes for the appointment and removal of the external auditor and the rotation of the audit engagement partner.	N/A	date of this report the Committee comprises of three members, the majority of whom are independent Directors and the Chair of the Committee is not the Chair of the Board as follows: • Andrew Maxwell – Independent Chairman • Adam Darkins – Independent Member • Chris Indermaur – independent Member • Jack Cosentino – non-independent member Refer Company's Audit & Risk Committee Charter which is located on the Company's website at the following link: http://www.medibio.com.au/corporate-governance/ For further information refer to the Company's Annual Report which is located on the Company's website at the following link: http://www.medibio.com.au/corporate-governance/
Recommendation 4.2		
The board of a listed entity should, before it approves the entity's financial	Yes	The CEO and CFO execute Section 295A declarations and submit to the
statements for a financial period, receive from its CEO and CFO a declaration		Audit Committee and Board prior to approving the Annual Report.
that the financial records of the entity have been properly maintained and		
that the financial statements comply with the appropriate accounting		

PRINCIPLES AND RECOMMENDATIONS	COMPLY (YES/NO)	EXPLANATION
standards and give a true and fair view of the financial position and performance of the entity and that the opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.		
Recommendation 4.3 A listed entity that has an AGM should ensure that its external auditor attends its AGM and is available to answer questions from security holders relevant to the audit.	Yes	The Auditor attends the Company Annual General Meeting

Principle 5: Make timely and balanced disclosure

Recommendation 5.1		
A listed entity should:	Yes	Refer to the Company's Continuous Disclosure Policy for further detail
(a) have a written policy for complying with its continuous disclosure		which is located on the Company's website at the following link:
obligations under the Listing Rules; and	Yes	http://www.medibio.com.au/corporate-governance/
(b) disclose that policy or a summary of it.		

Principle 6: Respect the rights of security holders

Recommendation 6.1 A listed entity should provide information about itself and its governance to investors via its website.	Yes	Refer to the Company's Investor Relations Policy for further detail which is located on the Company's website at the following link: http://www.medibio.com.au/corporate-governance/
Recommendation 6.2 A listed entity should design and implement an investor relations program to facilitate effective two-way communication with investors.	Yes	Refer to the Company's Investor Policy for further detail which is located on the Company's website at the following link: http://www.medibio.com.au/corporate-governance/
Recommendation 6.3 A listed entity should disclose the policies and processes it has in place to facilitate and encourage participation at meetings of security holders.	Yes	Refer to the Company's Investor Policy for further detail which is located on the Company's website at the following link: http://www.medibio.com.au/corporate-governance/

PRINCIPLES AND RECOMMENDATIONS	COMPLY (YES/NO)	EXPLANATION
Recommendation 6.4 A listed entity should give security holders the option to receive communications from, and send communications to, the entity and its security registry electronically.	Yes	Refer to the Company's Investor Relations Policies for further detail which is located on the Company's website at the following link: http://www.medibio.com.au/corporate-governance/

Principle 7: Recognise and manage risk

Recommendation 7.1		
The board of a listed entity should:		
(a) have a committee or committees to oversee risk, each of which:	(a) No	Due to the size of the Company and its Board, the Board will fulfil the
 (i) has at least three members, a majority of whom are independent directors; and (ii) is chaired by an independent director, and disclose: (iii) the charter of the committee; 	(i) Yes (ii) Yes (iii) Yes	roles and responsibilities in relation to the entity's risk management framework in the Audit & Risk Committee. Refer to Recommendation 4.1 for details and the composition of the
(iv) the members of the committee; and	(iv) Yes	Audit & Risk Committee
 (v) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or (b) if it does not have a risk committee or committees that satisfy (a) above, disclose that fact and the process it employs for overseeing the entity's risk management framework. 	(v) Yes (b) N/A	For further detail refer to the Company's Audit & Risk Committee Charter which is located on the Company's website at the following link: http://www.medibio.com.au/corporate-governance/
Recommendation 7.2		
 The board or a committee of the board should: (a) review the entity's risk management framework with management at least annually to satisfy itself that it continues to be sound, to determine whether there have been any changes in the material business risks the entity faces and to ensure that they remain within the risk appetite set by the board; and (b) disclose in relation to each reporting period, whether such a review has taken place. 	Yes to all	Management, through the Managing Director and Chief Executive Officer, is responsible for designing, implementing and reporting on the adequacy of the Company's risk management and internal control system. Management reports to the Audit & Risk Committee on the Company's key risks and the extent to which it believes these risks are being monitored at each Committee meeting. The Audit & Risk Committee review and monitor management's risk management and internal compliance and control systems.
		On a continuous basis the Board has charged the Committee with responsibility that:

PRINCIPLES AND RECOMMENDATIONS	COMPLY (YES/NO)	EXPLANATION
		 clearly describe the respective roles of the Board, the Committee and Management; and prescribe the necessary elements of an effective risk management system, namely, oversight, risk profile, risk management, compliance and control, and assessment of system effectiveness. Refer to the Company's Audit & Risk Committee Charter which is located on the Company's website at the following link: http://www.medibio.com.au/corporate-governance/
Recommendation 7.3 A listed entity should disclose: (a) if it has an internal audit function, how the function is structured and what role it performs; or (b) if it does not have an internal audit function, that fact and the processes it employs for evaluating and continually improving the effectiveness of its risk management and internal control processes.	a) N/A b) Yes	Given the size of the company, there is no internal audit function. Detailed risk assessments are carried out in respect of a wide range of items, and where appropriate and possible, risk mitigation strategies are implemented to minimise the chance of the risks occurring, and to minimise any impact where a risk eventuates. The Managing Director/CEO and Chief Financial Officer provide written confirmation to the Board in accordance with the requirements of Section 295A (2) of the Corporations Act 2001. This certification is founded on a sound system of risk management and internal compliance and control, which implement the policies adopted by the Board and the Company's risk management and internal compliance and control systems are operating efficiently and effectively in all material respects. Refer to the Company's Audit & Risk Committee Charter which is located on the Company's website at the following link: http://www.medibio.com.au/corporate-governance/
Recommendation 7.4 A listed entity should disclose whether, and if so how, it has regard to economic, environmental and social sustainability risks and, if it does, how it manages or intends to manage those risks.	No	The Board does not consider that the Company has any material environmental or social sustainability risks or exposures.

Principle 8: Remunerate fairly and responsibly

Recommendation 8.1		
The board of a listed entity should:		The Board has a Nomination & Remuneration Committee to assist the
a) have a remuneration committee which:	(a) Yes	Board in ensuring it is equipped to discharge its responsibilities. The
 (i) has at least three members, a majority of whom are independent directors; and (ii) is chaired by an independent director, and disclose: (iii) the charter of the committee; (iv) the members of the committee; and 	(i) Yes (ii) Yes (iii) Yes (iv) Yes	Committee has guidelines for the nomination and selection of directors and for the operation of the Board. Prior to 30 June 2017 due the size and nature of the Company's operations the Board had chosen to discuss those matters usually considered by the Nomination & Remuneration Committee on a regular basis at the full Board during its
(v) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances	(v) Yes	regular meetings.
of the members at those meetings; or b) if it does not have a remuneration committee, disclose that fact and the processes it employs for setting the level and composition of remuneration for directors and senior executives and ensuring that such remuneration is appropriate and not excessive.	(b) N/A	The Committee Comprises of: Chris Indermaur – Independent Member & Chairman Adam Darkins – Independent Member Andrew Maxwell – independent Member Michael Phelps (Peter Carlisle) – independent Member Refer to the Company's Charter which is located on the Company's website at the following link: http://www.medibio.com.au/corporate-governance/ Refer to the Company's 2017 Annual Report which is located on the Company's website at the following link: http://www.medibio.com.au/corporate-governance/
Recommendation 8.2 A listed entity should separately disclose its policies and practices regarding the remuneration of non-executive directors and the remuneration of executive directors and other senior executives.	Yes	Separate disclosure regarding the remuneration of the Company's directors (executive and non-executive) and CEO is disclosed in the Company's Annual report, as lodged with the ASX and issued to shareholders. A copy of the latest Annual Report containing this disclosure can be accessed at http://www.medibio.com.au/corporate-governance/

PRINCIPLES AND RECOMMENDATIONS	COMPLY (YES/NO)	EXPLANATION
	(YES/NO)	
Recommendation 8.3		
A listed entity which has an equity-based remuneration scheme should:	Yes	The Company has an equity based remuneration scheme approved.
(a) have a policy on whether participants are permitted to enter into		
transactions (whether through the use of derivatives or otherwise)		Details of remuneration are outlined in the Company 2017 Annual
which limit the economic risk of participating in the scheme; and		Report.
(b) disclose that policy or a summary of it.		